ArticleMedical oncology (Northwood, London, England)2026
Investigating the effects of platelets, platelet releasate and aspirin on colorectal cancer cell proliferation, migration and invasion.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aims of this study were to investigate the binding of platelets to colorectal cancer (CRC) cells, platelet activation by CRC cells, and determine the effect of platelets and platelet releasate containing extracellular vesicles on CRC cell proliferation, migration and invasion following aspirin pretreatment. Platelets from healthy individuals were pretreated with aspirin before co-incubation with CRC cells. Platelet activation by CRC cells was analysed by flow cytometry and the binding of platelets to CRC cells investigated using immunofluorescence microscopy. Platelet releasate containing extracellular vesicles was generated by centrifugation. The effect of platelets and platelet releasate on CRC cell proliferation was investigated using carboxyfluorescein succinimidyl esterand dimethylthiazol-carboxymethoxyphenyl-sulfophenyl-tetrazolium assays. Migration and invasion were examined using Transwell assays. HCT15 and HCT116 CRC cells activated platelets, with higher numbers of CRC cells activating more platelets, however aspirin was unable to inhibit platelet activation. Platelets are also able to bind to HCT15 and HCT116 cells. Platelets and platelet releasate did not affect HCT15 and HCT116 proliferation, however, aspirin directly inhibited the proliferation of both cell lines. Platelets and platelet releasate significantly increased the migration and invasion of HCT116, but not HCT15 cell lines. Platelets adhere to and are activated by CRC cells lines, with aspirin unable to inhibit this activation. CRC proliferation was not affected by platelets, however the effect on cancer cell migration and invasion was dependent upon the cell line, suggesting the effects of platelets and platelet releasate containing extracellular vesicles may be patient specific. The inhibitory effect of aspirin on colorectal cancer proliferation is a direct effect on the cancer cell and independent of platelets and extracellular vesicles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.